Remove Computational Chemistry Remove Drugs Remove Small Molecule
article thumbnail

AI in Drug Discovery - A Highly Opinionated Literature Review (Part III)

Practical Cheminformatics

Property Prediction Machine Learning Methods for Small Data Challenges in Molecular Science [link] Practical guidelines for the use of gradient boosting for molecular property prediction [link] Application of message passing neural networks for molecular property prediction [link] Molecular Similarity Molecular Similarity: Theory, Applications, and (..)

article thumbnail

The Data-Driven Future of Drug Development

DrugBank

Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drug development lifecycle.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. 2013) 56, 2059-2073.

article thumbnail

Sygnature Discovery and Daewoong Pharma announce research collaboration

Sygnature Discovery

Sygnature Discovery is pleased to have entered into a research collaboration agreement with the global healthcare group Daewoong Pharmaceutical to accelerate the discovery of a novel small molecule to target autoimmune disease.

article thumbnail

Reaching cruising altitude: New discovery tools to target RNA

Dark Matter Blog

The majority of small molecule drugs induce their therapeutic effects by seeking out and binding to their intended target while avoiding most other molecules in the dense milieu of the cell interior. Our overall mission at Arrakis is to expand the set of “druggable” targets for small-molecule medicines to include RNA.

RNA 52
article thumbnail

Accelerating Innovation, Deepening Integration | Viva Biotech Online Investor Day Review

The Pharma Data

Since its establishment, Viva Biotech has been providing comprehensive new drug R&D services to nearly 500 world’s top pharmaceutical and biotech companies based on Viva’s excellence in structure-based drug discovery. Dr. David Xu , CBO of Viva Biotech, described the development and future prospects of the EFS model.

article thumbnail

Women in Stem with Dr Rachel Lagiakos

Drug Target Review

My career choice was made from an early age when I was deeply affected by both my Uncle’s HIV+ diagnosis and then the extraordinary cocktails of antiretroviral drugs he took, which gave me another 20 years with him beyond his doctor’s initial grim projection. They are only going to do that when they feel valued and heard.